Online inquiry

IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8128MR)

This product GTTS-WQ8128MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8128MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3322MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ10919MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ8405MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ4856MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ12629MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ2837MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ10455MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ8922MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW